{"id":534437,"date":"2021-09-03T16:18:16","date_gmt":"2021-09-03T20:18:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/"},"modified":"2021-09-03T16:18:16","modified_gmt":"2021-09-03T20:18:16","slug":"anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/","title":{"rendered":"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PHILADELPHIA, Sept.  03, 2021  (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd. has increased its holding in one of its subsidiaries AnPai (Shanghai) Healthcare Management Consultant Co., Ltd. (AnPai) with approvals by its audit committee and board of directors. The company has carried out rigorous due diligence including financial and legal audits, as well as appraisals by a qualified appraiser. The company completed the share structure registration amendment with the local Administration Management Bureau in late August 2021.<\/p>\n<p>AnPai was founded in 2016, and historically served mainly as a distributor of Anpac Bio\u2019s cancer test products. AnPai has a track record of solid performance in last three years and has a diversity of customers and has consistently grown its revenues. Its potential customer channels and strong sales capability will help Anpac Bio with future access to a wider range of customers.<\/p>\n<p>Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: \u201cAnPac Bio is excited to have completed this important step. We are able to successfully incorporate with AnPai\u2019s wide diversity customers and high revenue growth through this transaction. In the future, we will achieve faster and greater progress and development in the diversity of customers and the professionalism of our services as well as projected sustainable revenue growth through our greater share ownership. We hope that customers will benefit from Anpac Bio\u2019s CDA technology.\u201d<\/p>\n<p>\n        <strong>About AnPac Bio<\/strong>\n      <\/p>\n<p>AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of\u00a0March 31, 2021. With one CLIA- and CAP-registered clinical laboratory in\u00a0the United States\u00a0and two certified clinical laboratories in\u00a0China, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), biochemical, immunological and genomics tests. According to a Frost &amp; Sullivan\u2019s report issued in 2020, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The Company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of\u00a0March 31, 2021. AnPac Bio\u2019s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.<\/p>\n<p>For more information, please visit: https:\/\/www.Anpacbio.com.<\/p>\n<p>\n        <strong>For investor and media inquiries, please contact: <\/strong>\n      <\/p>\n<p>\n        <em>Company:<\/em><br \/>\n        <br \/>Phil Case, Marketing and Investor Relations<br \/>Phone: +1-267-810-6776 (US)<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0Uok79YEjkJin4nClNRgOy_rKFpsN7UOqcm2OtWyDv5bU09ReEN1NwKABTdEeeNr6MgfGdOrGpTV2isTtZkVOpgHu5pWDgQUxNbGmu16C6o=\" rel=\"nofollow noopener\" target=\"_blank\">phil_case@AnPacbio.com<\/a><\/p>\n<p>\n        <em>Investor Relations:<\/em><br \/>\n        <br \/>Ascent Investor Relations LLC<br \/>Tina Xiao, President<br \/>Phone: +1-917-609-0333 (US)<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wQpXMgHISV-9bHqnFMHcYXjVgFLIDpSvEyOkNvtprn2Kp21GKykzvuTqccAVIPzxR5DNNNnNGfP5Cb3S34YVB4TWXoafcMKvhy5Ep8vYfE8=\" rel=\"nofollow noopener\" target=\"_blank\">tina.xiao@ascent-ir.com<\/a>\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p>This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company\u2019s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cpredict,\u201d \u201coutlook,\u201d \u201cseek,\u201d \u201cgoal\u201d \u201cobjective,\u201d \u201cassume,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cpositioned,\u201d \u201cforecast,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company\u2019s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the \u201cRisk Factors\u201d detailed from time to time in the Company\u2019s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTgyMDU2OWQtNTA1Yi00YzVkLTk1YWMtMTM1MTZkNTllODFkLTEyMDUyNDc=\/tiny\/Anpac-Bio-USA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd. has increased its holding in one of its subsidiaries AnPai (Shanghai) Healthcare Management Consultant Co., Ltd. (AnPai) with approvals by its audit committee and board of directors. The company has carried out rigorous due diligence including financial and legal audits, as well as appraisals by a qualified appraiser. The company completed the share structure registration amendment with the local Administration Management Bureau in late August 2021. AnPai was founded in 2016, and historically served mainly as a distributor &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534437","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd. has increased its holding in one of its subsidiaries AnPai (Shanghai) Healthcare Management Consultant Co., Ltd. (AnPai) with approvals by its audit committee and board of directors. The company has carried out rigorous due diligence including financial and legal audits, as well as appraisals by a qualified appraiser. The company completed the share structure registration amendment with the local Administration Management Bureau in late August 2021. AnPai was founded in 2016, and historically served mainly as a distributor &hellip; Continue reading &quot;AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-03T20:18:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%\",\"datePublished\":\"2021-09-03T20:18:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/\"},\"wordCount\":966,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/\",\"name\":\"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=\",\"datePublished\":\"2021-09-03T20:18:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/","og_locale":"en_US","og_type":"article","og_title":"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% - Market Newsdesk","og_description":"PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that its subsidiary, Anpac Bio-Medical Science (Lishui) Co., Ltd. has increased its holding in one of its subsidiaries AnPai (Shanghai) Healthcare Management Consultant Co., Ltd. (AnPai) with approvals by its audit committee and board of directors. The company has carried out rigorous due diligence including financial and legal audits, as well as appraisals by a qualified appraiser. The company completed the share structure registration amendment with the local Administration Management Bureau in late August 2021. AnPai was founded in 2016, and historically served mainly as a distributor &hellip; Continue reading \"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-03T20:18:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%","datePublished":"2021-09-03T20:18:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/"},"wordCount":966,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/","name":"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=","datePublished":"2021-09-03T20:18:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMDE2OCM0Mzg4OTYwIzIxOTM2OTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20-to-60\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534437"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534437\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}